Mesenchymal stem cells in knee osteoarthritis treatment: A systematic review and meta-analysis

Song, Yancheng; Zhang, Junhui; Xu, Haiyan; Lin, Zhujian; Chang, Hong; Liu, Wei; Kong, Ling

doi:10.1016/j.jot.2020.03.015

Cited by 89 publications

(113 citation statements)

References 47 publications

(130 reference statements)

Supporting

Mentioning

111

Contrasting

Unclassified

Order By: Relevance

“…These observations were further reinforced in another meta-analysis including 19 studies (15 RCTs, 2 retrospective studies, and 2 cohort studies, of which 9 studies were with AD-MSCs, 5 with BM-MSCs, peripheral blood stem cells in 1 study, and MSCs from a fetus in 4 studies) that found statistically significant pain relief effectiveness measured by the VAS at 12 months’ and KOOS and WOMAC at 6 months’ follow-up. The included studies demonstrated no side-effects of intra-articular MSC therapy [ 102 ]. In a systematic review and meta-analysis by Maheshwer and colleagues including 25 studies, a different result was observed, as demonstrated by no significant pain improvement, but a functional and cartilage volume improvement (0.66 and 0.84 standardized mean difference (SMD), respectively) [ 103 ].…”

Section: Intra-articular Injectionsmentioning

confidence: 99%

Comprehensive Review of Knee Osteoarthritis Pharmacological Treatment and the Latest Professional Societies’ Guidelines

Primorac

Molnar

Matišić³

et al. 2021

Pharmaceuticals

View full text Add to dashboard Cite

Osteoarthritis is the most common musculoskeletal progressive disease, with the knee as the most commonly affected joint in the human body. While several new medications are still under research, many symptomatic therapy options, such as analgesics (opioid and non-opioid), nonsteroid anti-inflammatory drugs, symptomatic slow-acting drugs in osteoarthritis, and preparations for topical administration, are being used, with a diverse clinical response and inconsistent conclusions across various professional societies guidelines. The concept of pharmacogenomic-guided therapy, which lies on principles of the right medication for the right patient in the right dose at the right time, can significantly increase the patient’s response to symptom relief therapy in knee osteoarthritis. Corticosteroid intra-articular injections and hyaluronic acid injections provoke numerous discussions and disagreements among different guidelines, even though they are currently used in daily clinical practice. Biological options, such as platelet-rich plasma and mesenchymal stem cell injections, have shown good results in the treatment of osteoarthritis symptoms, greatly increasing the patient’s quality of life, especially when combined with other therapeutic options. Non-inclusion of the latter therapies in the guidelines, and their inconsistent stance on numerous therapy options, requires larger and well-designed studies to examine the true effects of these therapies and update the existing guidelines.

show abstract

Section: Intra-articular Injectionsmentioning

confidence: 99%

Comprehensive Review of Knee Osteoarthritis Pharmacological Treatment and the Latest Professional Societies’ Guidelines

Primorac

Molnar

Matišić³

et al. 2021

Pharmaceuticals

View full text Add to dashboard Cite

show abstract

“…In human research, study results strongly suggest that MSC therapy is effective in relieving pain and improving joint function in patients suffering from OA. Especially the effect on knee OA has been investigated thoroughly (22)(23)(24). Moreover, since no obvious adverse effects are described, MSC use in humans might be a safe and effective alternative for current OA management therapies (22,23).…”

Section: Upcoming Importance Of Mesenchymal Stem Cells In the Osteoarthritis Research Fieldmentioning

confidence: 99%

Review: Mesenchymal Stem Cell Therapy in Canine Osteoarthritis Research: “Experientia Docet” (Experience Will Teach Us)

et al. 2021

View full text Add to dashboard Cite

Osteoarthritis (OA) is currently an incurable and progressive condition in dogs causing chronic joint pain and possibly increasing disability. Due to the poor healing capacity of cartilage lesions that occur with OA, development of effective therapeutics is difficult. For this reason, current OA therapy is mostly limited to the management of pain and inflammation, but not directed ad disease modification. In the search for a safe and effective OA treatment, mesenchymal stem cells (MSCs) have been of great interest since these cells might be able to restore cartilage defects. The designs of OA studies on MSC usage, however, are not always consistent and complete, which limits a clear evaluation of MSC efficacy. The general study results show a tendency to improve lameness, joint pain and range of motion in dogs suffering from naturally-occurring OA. Assessment of the cartilage surface demonstrated the ability of MSCs to promote cartilage-like tissue formation in artificially created cartilage defects. Immunomodulatory capacities of MSCs also seem to play an important role in reducing pain and inflammation in dogs. It should be mentioned, however, that in the current studies in literature there are specific design limitations and further research is warranted to confirm these findings.

show abstract

“…Stem cells possess a therapeutic effect through differentiation ability, immunity regulation, antiinflammatory, improving microenvironmental conditions, and enhancing the regeneration process [25]. MSC have multipotent progenitor capabilities derived from adult stem cell (ASC) populations that can be found in some tissues such as bone marrow, peripheral blood, adipose tissue, synovium tissue and fluid, placenta, and umbilical cord.…”

Section: Stem Cells Therapy For Oamentioning

confidence: 99%

Clinical Application Prospect of Human Synovial Tissue Stem Cells from Osteoarthritis Grade IV Patients in Cartilage Regeneration

Rahmadian

Adly

Dilogo

et al. 2021

Open Access Maced J Med Sci

View full text Add to dashboard Cite

Osteoarthritis (OA) is a joint problem that continues to increase in prevalence as life expectancy increases. OA can affect any joint, especially those that support body weight such as the knee and hip joint. Although both primary and secondary OA have the same clinical symptoms, it can be caused by different etiologies. OA is no longer considered a degenerative disease, although age is still a major factor. Various attempts have been made to regenerate joint cartilage damaged by OA. The use of stem cells in OA therapy is a very promising opportunity. Stem cells are undifferentiated biological cells and are multipotent to differentiate into specific cells. In principle, local stem cells are the best source of stem cells to regenerate the surrounding tissue. The synovial membrane is a tissue in the joint that can regenerate. After synovectomy surgery, repair, and growth of synovial tissue occur rapidly. Synovial tissue as a source of stem cells only provides a limited amount. One source of synovial tissue that can be used is tissue taken from the total knee replacement process in grade 4 OA patients. However, it is necessary to prove the potential of synovial tissue stem cells originating from old-age donors.

show abstract

Mesenchymal stem cells in knee osteoarthritis treatment: A systematic review and meta-analysis

Cited by 89 publications

References 47 publications

Comprehensive Review of Knee Osteoarthritis Pharmacological Treatment and the Latest Professional Societies’ Guidelines

Comprehensive Review of Knee Osteoarthritis Pharmacological Treatment and the Latest Professional Societies’ Guidelines

Review: Mesenchymal Stem Cell Therapy in Canine Osteoarthritis Research: “Experientia Docet” (Experience Will Teach Us)

Clinical Application Prospect of Human Synovial Tissue Stem Cells from Osteoarthritis Grade IV Patients in Cartilage Regeneration

Contact Info

Product

Resources

About